(Q35782899)

10 August 2017

1 reference

title

Gemcitabine (Gemzar) in non-small cell lung cancer (English)

1 reference

10 August 2017

1 reference

Christian Manegold

1

1 reference

10 August 2017

publication date

1 June 2004

1 reference

Expert Review of Anticancer Therapy

10 August 2017

published in

1 reference

10 August 2017

volume

4

1 reference

10 August 2017

issue

3

1 reference

10 August 2017

page(s)

345-360

1 reference

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer: a National Cancer Institute of Canada Clinical Trials Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

Neoadjuvant chemotherapy with gemcitabine and cisplatin in stage IIIA/B non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.345

21 January 2018

Identifiers

DOI

10.1586/14737140.4.3.345

1 reference

10 August 2017

1 reference